NIVOPOSTOP Trial Results: A Landmark Breakthrou...

By João L. Carapinha

September 23, 2025

The NIVOPOSTOP trial results represent a landmark breakthrough in head and neck cancer treatment. Adding nivolumab immunotherapy to standard post-surgical radiotherapy and cisplatin significantly improved disease-free survival in high-risk patient...
Addressing GLP-1 Access Inequity: Lessons from HIV/AIDS Mobilization
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascul...
Medicare ACO Outcomes: Balancing Surgical Benefits and Costs Under the TEAM M...
Impact of Generic Liraglutide Launch on Weight Management and Health Economics
Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidiscipl...
Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflamma...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Unlocking Self-Care South Africa: Strategies and Challenges in Healthcare Reform
PADCEV KEYTRUDA Urothelial Cancer: Advancements in Survival Outcomes and Econ...
FDA Approved Eye Drops: Lenz Therapeutics Launches VIZZ for Presbyopia Treatment